---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-107312"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:54:01.785908+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics reports zovegalisib + fulvestrant Phase 1/2 data: 11.1 mo median PFS at RP3D

## Summary
- Median PFS of 11.1 months (95% CI 7.3-13.0) in 57 evaluable PI3Kα-mutated HR+/HER2- mBC patients.
- Confirmed ORR 43% overall (15/35) and 52% in second-line patients (11/21).
- Safety consistent with prior 600mg fasted; only 4 of 60 patients discontinued due to TRAEs.
- Pharmacokinetics of 400mg BID fed comparable to 600mg BID fasted; most patients above IC80.
- FDA Breakthrough Therapy designation already granted; Phase 3 ReDiscover-2 trial ongoing since mid-2025.

## SEC filing metadata
- accession: 0001193125-26-107312
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000119312526107312/0001193125-26-107312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000119312526107312/rlay-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-107312
- JSON: https://secwatch.observer/filing/0001193125-26-107312.json
- Plain text: https://secwatch.observer/filing/0001193125-26-107312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.